These drugs are the latest in a growing list of oncology medications in short supply:
Azacitidine injections: Three drugmakers stopped making 100 milligram solutions of the leukemia drug.
Iobenguane I-131 injections: Progenics Pharmaceuticals stopped making two solutions because of low demand for the oncology medication.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
